Methylation markers in early-stage lung cancer with ablation therapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if a special treatment called co-ablation can help people with early-stage non-small cell lung cancer who cannot or choose not to have surgery. It also looks at certain markers in the blood to better understand the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that was confirmed by a biopsy or other test and cannot be removed with surgery.
- You are between 18 and 85 years old.
- Your tumor must be 5 cm or smaller if it is in the outer part of the lung, or 3 cm or smaller if it is near the center of the lung.
- You must be well enough to do normal daily activities (ECOG score 0 or 1) and have a life expectancy of at least 6 months.
- You cannot have had other cancers or autoimmune diseases.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses special markers in the blood to find lung cancer early and track if it comes back after treatment. It is for people with non-small cell lung cancer who are able to have surgery.
This trial tests combining microwave ablation (heat treatment of tumors) with two drugs—tislelizumab (an immune-boosting drug) and docetaxel (chemotherapy)—for patients with advanced non-small cell lung cancer whose disease progressed after initial immunotherapy. The goal is to see if this combination can slow or shrink tumors better than standard treatment alone.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This trial tests whether combining a tumor-destroying procedure (ablation) with immunotherapy (tislelizumab) and chemotherapy before surgery can improve outcomes for people with stage II-IIIB non-small cell lung cancer. The goal is to shrink the tumor and boost the immune system to fight the cancer more effectively.
This trial tests whether adding adalimumab to standard anti-cancer treatment can improve outcomes for people with non-small cell lung cancer that can be surgically removed. It aims to see if this combination is safe and effective before surgery.
This trial combines diagnosis and treatment in one procedure for small lung nodules. Doctors use a special tube to look inside the airways, take a sample, and then destroy the tumor with heat or cold (ablation). This may help people who cannot have surgery.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.